Lacosamide controls seizures by targeting sodium channels in the brain, but through a mechanism that’s fundamentally different from older seizure medications. While drugs like carbamazepine and phenytoin work by enhancing “fast inactivation” of sodium channels, lacosamide is the only anticonvulsant that selectively enhances “slow inactivation,” a distinct process that quiets overactive neurons without broadly suppressing normal brain signaling.
Slow vs. Fast Sodium Channel Inactivation
To understand what makes lacosamide unique, it helps to know how sodium channels work. Neurons fire by opening tiny sodium channels in their membranes, letting sodium ions rush in and creating an electrical signal. After firing, these channels temporarily shut down through a process called inactivation, which prevents the neuron from firing again immediately. There are two types of inactivation: fast and slow.
Fast inactivation happens within milliseconds after every single firing. It’s the brief reset between normal nerve impulses. Traditional sodium channel blockers like carbamazepine, phenytoin, and lamotrigine all enhance this fast inactivation, making channels stay shut a little longer after each firing. This approach works, but it affects neurons broadly, even ones firing at normal rates.
Slow inactivation is a deeper, longer-lasting shutdown that kicks in when a neuron has been firing repeatedly or excessively over seconds. Think of it as a safety valve: the more a neuron overworks, the more channels enter this slow inactivated state, reducing excitability. Lacosamide enhances this process specifically. It shifts the voltage threshold for slow inactivation, making it easier for channels to enter this prolonged resting state, and it speeds up how quickly channels transition into slow inactivation.
Critically, lacosamide does not alter fast inactivation at all. In laboratory studies, it didn’t shift the fast inactivation voltage curve, didn’t slow recovery from fast inactivation, and didn’t produce the frequency-dependent blocking pattern that characterizes traditional sodium channel drugs. A brief period of rest at normal resting voltage removes the effects of carbamazepine and similar drugs, but it does not remove lacosamide’s effects. This selectivity means lacosamide preferentially targets neurons that are pathologically hyperactive, the kind that drive seizures, while leaving normally firing neurons relatively undisturbed.
Why This Distinction Matters for Seizure Control
During a seizure, groups of neurons fire rapidly and synchronously in a self-reinforcing loop. Because lacosamide’s effect grows stronger the more a neuron fires over sustained periods, it acts like a brake that tightens proportionally to how out of control the firing becomes. Neurons humming along at their usual pace barely notice the drug, while neurons caught in a seizure pattern get progressively suppressed.
This selective mechanism is one reason lacosamide can be effective when added to traditional sodium channel blockers. Since it works through a completely separate gating process, it’s not redundant with those older drugs. It’s targeting a different piece of the channel’s behavior.
A Possible Secondary Mechanism
Beyond sodium channels, lacosamide interacts with a protein involved in how neurons grow and extend their connections. This protein normally promotes the assembly of structural components inside nerve cells, helping them sprout new branches. Lacosamide impairs this assembly process, which in animal studies prevented excessive growth of neuronal connections driven by heightened activity. Whether this contributes meaningfully to seizure control in humans remains unclear, but it could play a role in the drug’s broader effects on neural network excitability.
What Lacosamide Treats
Lacosamide (brand name Vimpat) is FDA-approved for two types of seizures. It treats focal-onset seizures (previously called partial-onset seizures) in patients as young as one month old, either alone or alongside other medications. It’s also approved as add-on therapy for primary generalized tonic-clonic seizures in patients four years and older.
How the Body Processes Lacosamide
One of lacosamide’s practical advantages is its near-complete absorption when taken by mouth. Oral bioavailability is approximately 100%, meaning the pill form delivers essentially the same amount of drug to your bloodstream as an IV infusion. This makes switching between oral and intravenous forms straightforward, which matters in hospital settings.
The drug has an elimination half-life of about 13 hours, which is why it’s typically taken twice daily to maintain steady levels. It’s processed in the liver by several enzyme pathways, but it doesn’t significantly interfere with those same enzymes when breaking down other medications. It also binds very little to proteins in the blood (less than 15%), which reduces the likelihood of it competing with other drugs for space on those proteins. In practical terms, lacosamide has a relatively clean interaction profile compared to many seizure medications.
Drug Interactions Worth Knowing
While lacosamide doesn’t strongly affect the metabolism of other drugs, the reverse isn’t always true. Older seizure medications like carbamazepine, phenobarbital, and phenytoin can lower lacosamide levels by 15% to 20%. For most people this modest reduction doesn’t require adjustment, but your prescriber may account for it when setting your dose.
People with impaired kidney or liver function who also take strong inhibitors of certain liver enzymes may see lacosamide levels rise significantly, sometimes requiring a dose reduction. The more clinically relevant interaction involves heart rhythm: lacosamide can slightly lengthen the PR interval on an ECG (the time it takes electrical signals to travel through the upper chambers of the heart). If you’re also taking beta-blockers, calcium channel blockers, or other drugs that slow cardiac conduction, the combined effect could occasionally cause a meaningful delay. An ECG before starting lacosamide and after reaching a stable dose is typically recommended in these situations.
Effects on Heart Rhythm
The PR interval prolongation deserves some context because it’s the most commonly flagged safety concern. In clinical studies of intravenous lacosamide, the average increase was about 6 milliseconds, a change that was statistically measurable but not clinically significant for most patients. Occasional cases of new first-degree heart block have been reported, but these have generally been asymptomatic and resolved without treatment. Blood pressure changes (around 10 mmHg diastolic) were similarly mild.
The patients who need closer monitoring are those with pre-existing conduction abnormalities, structural heart disease, significant kidney or liver impairment, or advanced age. For a typical adult without these risk factors, the cardiac effects of lacosamide are minimal.
Typical Dosing Pattern
When used as the sole seizure medication, adults usually start at 100 mg twice daily. When added to an existing regimen, the starting dose is lower: 50 mg twice daily, gradually increased. Either way, the dose is titrated upward over weeks based on how well seizures are controlled and how well you tolerate the drug. The usual maximum is 400 mg per day, split into two doses. Some protocols allow a single 200 mg loading dose at the start, followed by the standard twice-daily schedule about 12 hours later, which helps reach effective blood levels faster.